Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc (NASDAQ: MRNA) is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster. What Happened: The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S. Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.

Moderna Seeks FDA Approval For COVID-19 Booster Shot

Moderna Inc. MRNA, +3.52% said late Wednesday it is submitting documents to the U.S. Food and Drug Administration (FDA) for the evaluation of a booster dose of its COVID-19 vaccine as a 50-microgram dose. The biotech company said it expects to submit data to European authorities and others around the world in the coming days.

Moderna asks FDA to evaluate COVID-19 vaccine booster candidate

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces submission of initial data to U.S. FDA for its COVID-19 vaccine booster.

Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster

DexCom

U.S. indices had a mixed day of trading Wednesday as investors weigh rising COVID-19 Delta variant cases nationwide. The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) gained 0.17% to $380.58

Moderna And DexCom Lead The Nasdaq-100

The reasons to get vaccinated keep piling up.

Why Shares of Moderna Are Up Today

Pfizer

Pfizer and Moderna have experienced tremendous success with their COVID-19 vaccines recently, which have swelled their coffers. Despite that, the Street is projecting a decline in revenue for both companies in the next few years.

Pfizer Vs. Moderna Stock: Which Is The Better Buy?

Moderna, Inc. (NASDAQ: MRNA) found itself in a controversy after Japan suspended the use of about 2.6 million doses of the company's COVID-19 vaccine following reports of contamination. Three lots of Moderna's COVID-19 vaccine — lot numbers 3004667, 3004734 and 3004956 — were suspended following reports from vaccination sites of a potential foreign particulate substance observed in unused vials from lot 3004667.

Moderna Reviews Contamination In Vaccine Lot Distributed In Japan

Let's look to rival Pfizer for some clues.

How Close Is the Moderna Vaccine to Approval? (And What Does That Mean for the Stock?

According to a study in Belgium, Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine generated more than double the antibodies than the shot made by Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX).  The research study assessed almost 2,500 workers at a major Belgium hospital system, directly comparing immune responses.

Moderna's COVID-19 Shot Elicits Higher Antibodies Than Pfizer/BioNTech Jab, Study Suggests

Japan allows use of uncontaminated vials from the same lots of Moderna's (MRNA) COVID-19 vaccine that had some contaminated vials, which led to the temporary halt of vaccination in some parts of the country.

Moderna (MRNA) Japan Jabs Resume Amid Safety Risk Per Reports

Moderna has been a great investment one or two years ago - but history doesn't necessarily repeat.

Can Moderna Stock Reach $500? What To Consider

The global tally for the coronavirus-borne illness climbed above 217 million on Tuesday, while the death toll rose to 4.51 million, according to data aggregated by Johns Hopkins University. The U.S. leads the world with a total of 39 million cases and 638,715 deaths.

Coronavirus tally: Global cases of COVID-19 top 217 million as study finds Moderna vaccine produced more antibodies than Pfizer's

BioNTech SE

A study comparing individual immune responses to two major COVID-19 vaccines has shown that Moderna's created more than double the antibodies than that of Pfizer and BioNTech.

Moderna's COVID-19 vaccine created more antibodies than Pfizer/BioNTech's in study of vaccinated Belgian health-care workers

The Japanese health minister's clarification comes a day after two Japanese prefectures put their vaccine rollouts on hold over contamination concerns.

Japanese Health Minister Says Vaccine Contaminants Likely Caused By Incorrect Needle Use, No Safety Issue With Moderna Shot

Moderna Inc (NASDAQ: MRNA) shares closed almost 3% lower in the regular session on Monday. What's Moving?

Why Moderna Shares Dropped Lower Today

The shares of Moderna Inc (NASDAQ:MRNA) are down roughly 2% to trade at $374.58 this morning, after the pharmaceutical company said Japan suspended another 1 million doses of its Covid-19 vaccine, bringing the total of withdrawn shots up to 2.6 million.

Moderna Stock Moves Lower After Japan Suspends Shots

This COVID-19 vaccine maker has potential but a high price.

How to Buy Moderna for the Cost of a Penny Stock

Advanced Micro Devices

Best Buy

Salesforce

NVIDIA

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. This week, our deep-learning algorithms have identified Moderna among others.

Moderna, Inc Ranked Among This Week's Trending Stocks Among COVID-19 Concerns And Vaccine Mandates

Japan's health ministry last week halted the use of 1.63 million Moderna vaccine doses after discovering “foreign materials” in some portions of unused doses.

Japan Finds More Contaminants In Moderna Vaccines, Suspends Use Of Additional 1 Million Doses

After receiving reports on more contaminated vials and two deaths, Japan has suspended another million doses of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine. Black substances were spotted in syringes and a vial, while pink substances were found in a different syringe filled with vaccines at the Okinawa center, Reuters reported citing NHK.

Moderna Withdraws Additional COVID-19 Shots In Japan: What You Need To Know

Gilead Sciences

It's too early for a "yes" answer. But it's too premature for a "no" response as well.

Could Moderna Take Down Gilead Sciences?

Moderna (NASDAQ: MRNA) shares are trading lower after Japan on Thursday suspended 1.6 million doses of the company's COVID-19 vaccine following contamination reports. Japan's health ministry said that 'foreign materials' were found in some doses of a batch of COVID-19 vaccines and suspended the batches out of an 'abundance of caution.

Why Moderna Shares Moved Lower Today

Moderna Inc. (NASDAQ: MRNA) stock seems to be running out of steam. Shares of the company climbed by about 300% between April to early August on the back of its vaccine that showed 94% efficacy against the Coronavirus.

Here's why Moderna shares are down about 5.0% on Friday

Japan stopped the use of 1.63 million Moderna doses after its health ministry reported foreign substances in some unopened vaccine vials.

EU says the plant that produced 1.63 million Moderna doses Japan halted the use of because of possible contamination can keep producing vaccines

Carrier Global

Regeneron Pharmaceuticals

We have narrowed down our search to five U.S. corporate bigwigs that have provided more than 10% returns in the past month. These are: MRNA, REGN, AIG, CARR and NVDA.

News for Moderna Stock (MRNA)